Recombinant Human IL5RA Protein, MYC/DDK-tagged, C13 and N15-labeled

• Cat.No.: IL5RA-251H
• Product Overview: IL5RA MS Standard C13 and N15-labeled recombinant protein (NP_783854) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.

Specification

• Description: The protein encoded by this gene is an interleukin 5 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL5 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL5. This protein has been found to interact with syndecan binding protein (syntenin), which is required for IL5 mediated activation of the transcription factor SOX4. Several alternatively spliced transcript variants encoding four distinct isoforms have been reported. [provided by RefSeq, Jul 2011]
• Source: HEK293
• Species: Human
• Tag: Myc&DDK
• Molecular Mass: 37.5 kDa
• AA Sequence: MIIVAHVLLILLGATEILQADLLPD EKISLLPPVNFTIKVTGLAQVLLQW KPNPDQEQRNVNLEYQVKINAPKED DYETRITESKCVTILHKGFSASVRT ILQNDHSLLASSWASAELHAPPGSP GTSIVNLTCTTNTTEDNYSRLRSYQ VSLHCTWLVGTDAPEDTQYFLYYRY GSWTEECQEYSKDTLGRNIACWFPR TFILSKGRDWLAVLVNGSSKHSAIR PFDQLFALHAIDQINPPLNVTAEIE GTRLSIQWEKPVSAFPIHCFDYEVK IHNTRNGYLQIEKLMTNAFISIIDD LSKYDVQVRAAVSSMCREAGLWSEW SQPIYVGKTRTRPLEQKLISEEDLA ANDILDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 3 months from receipt of products under proper storage and handling conditions.
• Storage: Store at -80 centigrade. Avoid repeated freeze-thaw cycles.
• Concentration: 50 μg/mL as determined by BCA
• Storage Buffer: 100 mM glycine, 25 mM Tris-HCl, pH 7.3.

Gene Information

• Gene Name: IL5RA interleukin 5 receptor, alpha [ Homo sapiens (human) ]
• Official Symbol: IL5RA
• Synonyms: IL5RA; interleukin 5 receptor, alpha; IL5R; interleukin-5 receptor subunit alpha; CD125; CDw125; CD125 antigen; IL-5R subunit alpha; IL-5 receptor subunit alpha; interleukin 5 receptor type 3; interleukin-5 receptor alpha chain; HSIL5R3; MGC26560
• Gene ID: 3568
• mRNA Refseq: NM_175727
• Protein Refseq: NP_783854
• MIM: 147851
• UniProt ID: Q01344

Reviews

04/05/2021

Good stability under different temperature and humidity conditions.

03/27/2021

In the process of purification, the removal of impurities is good.

11/13/2020

Chemical modifications, such as PEGylation or glycosylation, have little effect.

Q&As

What are the clinical applications of IL5RA?

Recombinant IL5RA can be used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. It can reduce the frequency and severity of asthma attacks by blocking the signaling of interleukin 5.

Can recombinant IL5RA be used to treat other diseases?

Currently, recombinant IL5RA is mainly used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. For other diseases, the suitability of IL5RA is subject to further research and clinical trials.

Does the use of IL5RA require blood routine examination?

During the use of IL5RA, the doctor may ask to check the patient's blood routine regularly to monitor changes in blood counts and related indicators. This helps to evaluate the efficacy of the treatment and the safety of the patient.

Does IL5RA cause dependence?

There is no clear evidence that long-term use of recombinant IL5RA causes dependence. For patients using IL5RA, it is best to treat and discontinue the drug according to the advice and guidance of their doctor.

What is the use of IL5RA?

IL5RA is generally administered by subcutaneous injection. The specific use method and dosage should be determined according to the doctor's recommendation and the specific situation of the patient.

What are the side effects of IL5RA?

Common side effects of recombinant IL5RA include pain at the injection site, redness and swelling at the injection site, cough, and sore throat. A small number of patients may experience allergic reactions or serious adverse reactions, so close monitoring of the patient's condition and signs is required when using.